Gastrointestinal Cancer Articles | Page 3

NCCN Recommends Regorafenib Dose Escalation in Metastatic CRC
The NCCN has updated its colorectal cancer (CRC) guidelines, recommending a weekly regorafenib dose-escalation strategy beginning at 80 mg and ending at 160 mg for previously treated patients with metastatic CRC.
FDA Approves 4-Week Nivolumab Dosing Schedule
The FDA has approved a supplemental biologics license application adding a 4-week dosing schedule for nivolumab across several of the PD-1 inhibitor’s indications.
Nut Consumption Linked to Survival Benefit in Colon Cancer
Patients with stage III colon cancer who ate at least 2 servings of nuts per week had superior disease-free survival and overall survival.
Strosberg Discusses Lutathera Approval, Remaining Challenges in NETs
Jonathan R. Strosberg, MD, discusses ongoing advances and challenges in the treatment of patients with NETs.
Expert Highlights Progress With Molecular Biomarkers in GI Cancers
Michael J. Pishvaian, MD, discusses expanded testing for biomarkers, using liquid biopsies to predict response to treatment, and the importance of identifying increasingly specific subsets of GI cancers to make treatment decisions.
Potentially Transformative Treatments Emerge in Pancreatic Cancer
Allyson Ocean, MD, discusses the development of novel therapeutic regimens in pancreatic cancer.
First Liver Transplant Surgery Performed in Patient With CRC Metastases
Although the standard-of-care treatment for patients with liver metastases developing from colorectal cancer is liver resection, only one-third of these patients are candidates for surgery.
Investigators are looking into a combination of immunotherapy agents for patients with unresectable hepatocellular carcinoma, for whom there are limited treatment options in the first line.
Aiwu Ruth He, MD, PhD, discusses the future of precision medicine in gastrointestinal cancers.
Lenvatinib HCC Data Published as FDA Considers Approval
Lenvatinib (Lenvima) was noninferior for overall survival while improving progression-free survival compared with sorafenib (Nexavar) for the frontline treatment of patients with unresectable hepatocellular carcinoma. 
Publication Bottom Border
Border Publication